{"disease":{"id":"mucopolysaccharidosis-type-iii","name":"mucopolysaccharidosis type iii"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03161171","title":"Parental Coping With Challenging Behavior in Mucopolysaccharidosis Type I-III","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT04201405","title":"Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT02618512","title":"A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}